50 filings analyzed. Top movers: Qorvo, Inc., Purple Innovation, Inc., PTC INC., INNOVATE Corp., SKYWORKS SOLUTIONS, INC..
8-K
Qorvo, Inc.
On October 5, 2026, Qorvo, Inc. merged with Comet Acquisition Corp. (a Skyworks Solutions subsidiary), with Qorvo surviving as Qorvo Technologies, LLC wholly owned by Skyworks. The transaction converts Qorvo from a public company into a single-member LLC governed by Skyworks' board. No purchase price, share count, or other financial terms are disclosed in this filing. The filing contains only organizational documents (LLC certificate and operating agreement) dated October 24, 2025 and October 5, 2026.
▼ Likely negative
· significance 95 · 8-K Agent
8-K
Purple Innovation, Inc.
Purple Innovation filed Form 8-K on October 5, 2026, reporting Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, with potential transfer of listing. The filing does not specify which exchange, which listing standard was violated, timeline for remediation, or specific stock price/volume violations. No financial impact figures are disclosed in the available filing text.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
PTC INC.
Schneider Electric SE agreed to acquire PTC Inc. in an all-cash merger for $205 per share (dated October 4, 2026). PTC has 108.6M shares outstanding as of October 2, 2026, implying ~$22.3B enterprise value. The merger agreement includes detailed representations on IP, government contracts, employee matters, and regulatory approvals (HSR, CFIUS, foreign antitrust). Closing is subject to shareholder vote, regulatory approvals, and customary closing conditions.
▲ Likely positive
· significance 88 · 8-K Agent
8-K
INNOVATE Corp.
INNOVATE completed the sale of DBM Global (91.21% stake) to IES Holdings on October 5, 2026. INNOVATE received approximately $378M in cash plus 430,974 IES shares (valued ~$146M), totaling ~$413M in cash at closing including a $35M Section 338 tax election payment. All proceeds will be used to reduce outstanding debt.
▲ Likely positive
· significance 87 · 8-K Agent
8-K
SKYWORKS SOLUTIONS, INC.
Skyworks closed its merger with Qorvo on October 5, 2026. Qorvo shareholders received $32.50 cash and 0.960 Skyworks shares per Qorvo share. The combined company targets $500M+ annual cost synergies within 24–36 months, expects immediate non-GAAP EPS accretion, and more than doubles addressable market. Legacy Skyworks shareholders own ~63%, legacy Qorvo shareholders ~37%, on fully diluted basis. Phil Brace remains CEO.
▲ Likely positive
· significance 79 · 8-K Agent
8-K
Alector, Inc.
Alector granted Genentech exclusive global rights to develop and commercialize AL050, a brain-penetrant GCase enzyme replacement therapy for Parkinson's disease and neurodegeneration, using Alector's proprietary ABC blood-brain barrier delivery platform. Alector receives $100 million upfront payment, up to $1.17 billion in milestone payments (development, regulatory, commercial), and tiered royalties on net sales. Genentech assumes all development, regulatory, manufacturing, and commercialization responsibility; Alector retains ABC platform ownership and rights to its wholly owned pipeline (AL137, AL164, AL062), with cash runway extended to 2029.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Distribution Solutions Group, Inc.
LKCM Headwater Investments, LLC (majority shareholder of Distribution Solutions Group, Inc.) announced a take-private transaction at $35.00 per share in cash, targeting ~21% minority equity. Financing consists of $700M aggregate principal of Senior Notes due 2032 (to be issued by Eclipse Acquisitions Merger Sub, Inc. and assumed by DSG post-close) plus $140M LKCM equity contribution. Proceeds will fund the $358M share acquisition consideration (net of cash), repay ~$195M of Term Loan A and $50M revolver borrowings, pay fees/expenses (~$26M), and retain $211M cash. Pro forma Total Net Leverage expected at 4.5x, targeting 3.5x–4.0x long-term. Transaction is conditional on stockholder approval and other customary closings.
— Neutral
· significance 78 · 8-K Agent
8-K
Vaxcyte, Inc.
Vaxcyte reported positive topline results from OPUS-1, a Phase 3 trial of VAX-31 (31-valent pneumococcal conjugate vaccine) in 4,047 adults. VAX-31 met all prespecified co-primary immunogenicity endpoints across age groups (50+, 18-49), demonstrating noninferiority on 28 shared serotypes vs. PCV20/PCV21, superiority on 3 unique serotypes, and comparable safety. The company expects to submit a BLA (Biologics License Application) in 1H 2028, pending results from OPUS-2 and OPUS-3 trials (anticipated 1H 2027).
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Stablecoin Development Corp
On January 16, 2026, SDEV completed a $134M private placement ($25M cash + $109M in SKY/stablecoins) for 167.5M pre-funded warrants. As of October 2, 2026, SDEV held ~2.32B SKY tokens (10% of total supply), acquired primarily through open-market purchases post-January 2026. The company stakes substantially all SKY in Sky Protocol, earning staking rewards (~67.1M SKY in H1 2026). SDEV's strategy focuses on long-term SKY acquisition and holding, with Sky Frontier Foundation and other January 2026 purchasers holding board nomination rights and a 24-month consent right over material strategy changes.
— Neutral
· significance 78 · 8-K Agent
8-K
RXO, Inc.
C.H. Robinson Worldwide, Inc. (Parent) agreed to acquire RXO, Inc. (Company) via two-step merger. RXO shareholders receive mix of cash ($17.25/share) and Parent stock (0.0856 ratio) with election rights, totaling stated equity value at signing date. Deal dated October 4, 2026; structure involves Merger Sub 1 merging into RXO (creating RXO Surviving Company), then RXO Surviving Company merges into NewCo LLC. Termination fee is $175M. Company stockholder approval required; closing expected ~3 business days after final regulatory/financing conditions met.
— Neutral
· significance 78 · 8-K Agent
8-K
Vulcan Infrastructure & Power Inc.
Vulcan announced October 13, 2026 redemption of $30.3M principal of 8.50% Senior Notes due 2026 (plus ~$523K accrued interest), totaling ~$30.9M payout. Prior to redemption, on October 1, 2026, the company exchanged $2.79M of 2026 Notes for $2.83M of 10.00% Senior Notes due 2030 and warrants for 1M shares at $1.87/share. Post-redemption, cash and digital assets expected to decline from $49.2M to $16.9M after redemption and ~$1.4M in PIPE expenses.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
SIM Acquisition Corp. I
SIM Acquisition Corp. I (market cap ~$239.7M) and American Industrial Technologies, Inc. (formerly Q1 Holdings) entered a binding Letter of Intent dated October 2, 2026, to combine via merger or acquisition. AIT shareholders will receive approximately 50,000,000 shares of the post-merger entity (Pubco). John Chiorando becomes CEO/Chairman; Pubco board will have 7 directors (4 from AIT, 3 from SIM). AIT must pay $5M termination fee if it withdraws; exclusivity runs through December 31, 2026. Closing contingent on due diligence, definitive agreements, regulatory approval, and Nasdaq listing standards. This replaces an earlier non-binding LOI from April 26, 2026.
— Neutral
· significance 78 · 8-K Agent
8-K
Axe Compute Inc.
Axe Compute completed acquisition of 100% ownership of Georgia AI cluster SPV from Duos Technologies on September 30, 2026, paying off $87.8M asset-backed loan at closing with no new equity issued. Total consideration includes $42.9M deferred purchase price payable monthly at $715,000 ($42.9M ÷ 12 months = ~$3.6M/month or $715k stated monthly installment over longer period). Customer agreement extended from 3 to 5 years through 2031; cluster contains 288 servers with 2,304 NVIDIA B300 GPUs; expected $364.6M lifetime revenue with improved gross margin; Duos covers facility and power costs for full 5-year term.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Jaguar Health, Inc.
Jaguar Health declared a special stock dividend of Series R Convertible Preferred Stock (2,325,000 shares authorized) to common shareholders and certain warrant holders as of record date October 13, 2026. Each Series R share converts to 5 common shares on November 2, 2026, creating ~11.6M conversion shares. The company simultaneously amended two $12M royalty agreements (Uptown Capital, Streeterville Capital) to raise minimum monthly payments to $750K effective January 1, 2027, and extended maturity of a $6.2M secured note to January 1, 2027.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
Tessera Defense & Homeland Security Inc.
Tessera Defense & Homeland Security Inc. entered into a Line of Credit Agreement dated October 5, 2026 with Mandragola Ltd. (an Israeli company), establishing a $5,000,000 credit facility that runs alongside a prior $2,000,000 credit line from the same lender. The new facility is evidenced by a 12% convertible promissory note maturing October 5, 2029; Mandragola can convert principal and accrued interest into Tessera common stock at the lower of (i) the lowest closing price in the five preceding trading days or (ii) $1.00 per share, subject to a 19.99% exchange cap requiring NYSE American stockholder approval. Mandragola is the same counterparty from whom Tessera purchased 100% of Mandragola's shareholdings in Dr. Frucht Systems Ltd. (representing 60% of DFSL's voting equity) in April 2026.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Fathom Holdings Inc.
Fathom Holdings and Neighborhood Intelligence (NXH) mutually terminated their merger agreement (originally dated June 16, 2026) effective October 5, 2026, citing inadequate valuations. Concurrently, Fathom amended its senior secured convertible notes: maturity extended to November 1, 2026, conversion price set at $0.65/share, interest rate increased to 18% per annum, and conversion capped at 19.99% of outstanding shares. No termination fees apply. NXH retains a Bridge Note with April 1, 2027 maturity; Fathom owes NXH up to $5,000 in legal fees.
▼ Likely negative
· significance 78 · 8-K Agent
SCHEDULE 13D/A
Target Hospitality Corp.
Manjit Dale, Gary Lindsay, and Thomas Mitchell each beneficially own 16,226,363 shares (16.6% of class). TDR Capital LLP and TDR Capital II Investments L.P. each hold 16.6%. Related entities Sapphire Holding, Arrow Holdings, MFA Holding, MFA SLP, and MFA Global collectively hold an additional 32.8%. Combined, these reporting persons control approximately 49.4% of Target Hospitality's 97.9M outstanding shares as of September 9, 2026.
— Neutral
· significance 78 · Ownership Agent
8-K
NOVAGOLD RESOURCES INC
NOVAGOLD is seeking shareholder approval (vote Nov. 3, 2026) to acquire Paulson Advisers LLC's 40% interest in Donlin Gold project for an all-share transaction, increasing NOVAGOLD's ownership from 60% to 100%. The deal creates a new U.S.-domiciled parent company (New NOVAGOLD) expected to have ~$4.9B market cap, with Citigroup issuing a fairness opinion. Directors, officers, and locked-up shareholders representing 28% of shares have committed to vote for approval.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Reliance Global Group, Inc.
Reliance Global Group completed the sale of Altruis Benefit Consulting on September 23, 2026, for $8 million in cash plus up to $1 million in earnout over three years. The company received approximately $7.5 million in net cash after a $3.1 million seller note was paid in full on September 30, 2026, with the remainder held as indemnity/working capital holdback. This is the second non-core asset sale under the company's portfolio monetization strategy to strengthen its balance sheet and fund AI platform development.
▲ Likely positive
· significance 78 · 8-K Agent
S-1
Evolution Metals & Technologies Corp.
Evolution Metals Technologies Corp. (market cap ~$7.1M) filed Form S-1 on October 5, 2026 to register resale of up to 5,400,000 common shares (par $0.0001) convertible from debentures issued to YA II PN, Ltd. under a Securities Purchase Agreement dated September 17, 2026. Multiple auditor consents filed; audits of operating subsidiaries (Handa Lab, KCM Industry, KMMI, NS World) and parent entities contain going-concern warnings. No transaction value disclosed in this exhibit package.
▼ Likely negative
· significance 78 · Registration Agent
8-K
NEIGHBORHOOD INTELLIGENCE, INC.
Neighborhood Intelligence and Fathom Holdings mutually terminated their proposed merger agreement on October 5, 2026, citing unfavorable valuations. NXH retains full ownership of its blockchain and digital asset investments (including tZERO stake) and will explore non-binding strategic collaborations with Fathom, such as data sharing. No specific financial terms, breakup fees, or asset valuations are disclosed.
— Neutral
· significance 72 · 8-K Agent
8-K/A
Processa Pharmaceuticals, Inc.
On July 28, 2026, Processa completed its acquisition of Vidya Therapeutics, Inc., acquiring the VT7208 BTK inhibitor program designed for autoimmune diseases (food allergy, CSU, MS). Concurrently, Processa raised $200 million gross proceeds from a private placement of non-voting convertible preferred stock from investors including Bain Capital Life Sciences, Janus Henderson, RA Capital, and others. The transaction fundamentally transformed Processa from a legacy pharma company into a clinical-stage immunology company focused on VT7208's development across three indications with Phase 2 trials planned for H2 2026 (food allergy, CSU) and H1 2027 (MS).
▲ Likely positive
· significance 72 · 8-K Agent
8-K
FORUM MARKETS Inc
Forum Markets (51% owner, manager) and Edge Node Inc (49%) formed Forum Edge AI LLC on October 2, 2026, to deploy inference GPU compute at ~11 MW across Dallas (2 MW operational, 4 MW Phase 0), High Point NC (6 MW Phase 0), and one tower site. Forum will issue ~1.46M shares (9.95% of Forum) to Edge Node upon power/financing milestones; Edge Node receives no cash upfront but gains GPU revenue share. Capital structure: $262M equipment financing (65% advance), $138M customer deposits, $42M JV equity (Forum's 51% share ~$22M). Phase 0 targets Q1-Q2 2027 energization; Forum projects $125-175M consolidated 2027 revenue.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
TELA Bio, Inc.
TELA Bio announced FDA 510(k) clearance on October 5, 2026 for Liora, a fully resorbable surgical mesh device for soft tissue reinforcement. Liora is the company's first fully resorbable synthetic product designed and manufactured in-house at its ISO 8 certified cleanroom in Malvern, PA. No financial impact, timeline, or commercial milestones were specified in the filing.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
C. H. ROBINSON WORLDWIDE, INC.
C.H. Robinson Worldwide, Inc. agreed to acquire RXO, Inc. via a two-step merger dated October 4, 2026. RXO shareholders receive mixed consideration: $17.25 cash plus 0.0856 Parent shares per share (Standard), or election of $30.25 all-cash or 0.1992 all-stock per share, subject to proration. Total consideration embedded in deal structure; specific aggregate dollar amount not stated in merger agreement itself.
— Neutral
· significance 72 · 8-K Agent
8-K
INTEST CORP
InTest Corporation reports estimated Q3 2026 orders of $48–$50M (up 28–33% YoY), driven by record back-end semiconductor orders, with revenue expected at the high end of guidance ($33–$35M, >30% growth vs. $26.2M in Q3 2025). Backlog at September 30, 2026 estimated at $58–$60M (up ~28–32% from $45.4M at June 30, 2026), with book-to-bill ratio above 1.3x. CEO cites AI-driven data center demand and new products (high-powered chillers, advanced manipulators) as drivers.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
NEUROONE MEDICAL TECHNOLOGIES Corp
NeuroOne reported preliminary FY2026 product revenue of $10.5M (15.6% YoY growth, at top of guidance), with Q4 revenue of $3.8M (38.4% YoY growth). In September 2026, the company secured a record $4.5M purchase order—its largest ever—with ~$1.0M shipped in September and $3.6M expected to ship in Q1–Q2 FY2027. Total open purchase orders reached $5.4M as of September 30, 2026.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
DUOS TECHNOLOGIES GROUP, INC.
Duos Technologies completed the sale of its GPU-as-a-Service entity to Axe Compute (NASDAQ: AGPU) on September 30, 2026, receiving $42.9 million in consideration payable over 60 months. The transaction eliminates approximately $98.1 million in prospective equipment financing obligations and allows Duos to refocus as a pure-play AI colocation landlord. The existing Columbus customer continues service under a revised five-year agreement with improved terms; Duos will lease GPU capacity from Axe Compute rather than owning it.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
PEOPLES BANCORP INC
Peoples Bancorp announced agreement to acquire Rockville, Maryland-based Capital Bancorp Inc. in an all-stock deal with fixed exchange ratio of 1.11 Peoples shares per Capital share, valued at ~$728M based on 20-day average price. Pro forma combined entity will have ~$14B assets, $10B loans, $11B deposits. Deal expected to close H1 2027; 19% EPS accretion fully phased in 2027, 10.8% tangible book value dilution with <3-year earn-back, >25% IRR. Peoples shareholders own ~2/3 post-close; three Capital directors join board.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Endovia Health Sciences, Inc.
The FDA Center for Veterinary Medicine determined that Endovia and Lupvindol's CannEpil (CBD/THC oral solution) qualifies as a Minor Use under the MUMS program for canine bone cancer pain, establishing eligibility for conditional approval. A formal pre-submission FDA conference is scheduled for November 19, 2026, and the companies are establishing U.S. manufacturing capabilities targeting a potential 2027 veterinary launch, subject to regulatory approval.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Granite Point Mortgage Trust Inc.
Granite Point amended its JPMorgan Chase repurchase agreement effective September 30, 2026, increasing the Maximum Facility Amount from unspecified prior level to $727M and paying a $156,684.93 amendment fee. Simultaneously, the interest coverage ratio covenant was relaxed: minimum ratio lowered to 1.20x for Q3–Q4 2026 (from 1.30x), then reset to 1.30x from Q1 2027 onward. Citi and Morgan Stanley repurchase facilities were fully repaid and are being terminated.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
GENERATION INCOME PROPERTIES, INC.
Generation Income Properties, L.P. (subsidiary of GIPR) amended its $5.2M secured promissory note with Brown Family Enterprises LLC, extending the maturity date from October 14, 2026 to October 14, 2027. The 9% interest rate, monthly payment terms, and security arrangements remain unchanged. The company acknowledged a $300K principal payment made on July 6, 2026.
— Neutral
· significance 72 · 8-K Agent
8-K
Fluent, Inc.
Fluent, Inc. (market cap ~$11.2M) filed an 8-K on October 5, 2026, reporting entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03). The filing document itself does not specify the counterparty, dollar amount, terms, or nature of the obligation—only that these items were triggered.
— Neutral
· significance 72 · 8-K Agent
8-K
Flyte Aviation, Inc.
Effective October 5, 2026, Catheter Precision, Inc. changed its name to Flyte Aviation, Inc. and its NYSE American ticker symbol from VTAK to VJET. The company is repositioning as a technology-enabled private aviation business targeting the $11.6B US private jet charter market (projected 6.9% CAGR to $16B by 2031). David Jenkins is CEO; Marc Sellouk founded Flyte in 2018. The company plans Q4 2026 investments in website, mobile app, digital marketing, and customer acquisition, and has partnered with the Hamptons International Film Festival as 'Official Air Travel Partner.' Life Sciences operations (LockeT, VIVO products) will continue with committed funding.
— Neutral
· significance 72 · 8-K Agent
8-K
Leslie's, Inc.
Leslie's Poolmart, Inc. (Borrower) and Leslie's, Inc. (Holdings), both debtors-in-possession under Chapter 11 filed September 30, 2026, entered into a superpriority secured DIP term loan credit agreement dated October 2, 2026. The facility provides up to $90 million in DIP term loans: $45 million in Interim DIP Term Loans and $45 million in Final DIP Term Loans, with Alter Domus (US) LLC as administrative and collateral agent. Interest rates are 6.50% for Term SOFR loans and 5.50% for ABR loans. Upfront fees (9.50%) and backstop premiums (7.00%) are capitalized as additional DIP term loans. Up to $15 million of principal plus capitalized interest may convert to equity on restructuring. Maturity is April 2, 2027 or upon plan consummation, whichever is earlier. The facility is secured by superpriority liens on substantially all assets and includes cash management and milestones requirements.
— Neutral
· significance 72 · 8-K Agent
8-K
BARNWELL INDUSTRIES INC
Barnwell Industries announced termination of its qualified defined benefit pension plan as of September 30, 2026. Plan assets of $12.8M exceed termination liability of $7.3M plus supplemental executive retirement obligations of $1.8M, yielding an estimated $3.7M net surplus (before taxes, administrative costs, and potential benefit increases). Reversion anticipated December 2026; actual proceeds depend on annuity pricing, interest rates, and final tax treatment.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
NRX Pharmaceuticals, Inc.
NRx Defense Systems, a subsidiary of NRx Pharmaceuticals (market cap ~$57.4M), was awarded an $11,177,757 DARPA contract to conduct the SPARC-TMS clinical trial testing robotic transcranial magnetic stimulation combined with NRX-101 for treatment-resistant depression. The trial, approved by FDA (NCT07227103), will be conducted at Harvard Medical School's McLean Hospital, Arizona State University, and HOPE Therapeutics, with potential expansion to military hospitals. If successful, the trial could serve as an FDA registration study for NRX-101 combined with TMS, targeting the 8.9 million American adults with treatment-resistant depression.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
UWM Holdings Corp
On August 5, 2026, UWM Holdings issued: (1) 200 million transferable subscription rights to Class A shareholders at $2.00/share minimum (85% VWAP floor), expiring November 12, 2026; (2) 1.5M Series A-1 Preferred shares and 150K Series A-2 Preferred shares at $1,000/share ($1.65B total) to Oaktree funds with 10-13% dividend rates, 60% redemption premium after year 5, and board control rights; (3) 165M Class A warrants ($6.00 strike) and 165M Class B warrants ($2.00 strike) to Ishbia parties and others, exercisable through August 2036. Oaktree receives two board seats and consent rights over major transactions. Total capital raised approximately $1.65B from preferred, plus warrant upside. Filing includes detailed governance terms: 79% voting cap on any holder, dividend parity requirements, liquidation preferences, and anti-takeover provisions.
— Neutral
· significance 72 · 8-K Agent
SCHEDULE 13D
Empire State Realty Trust, Inc.
Between Sept 2–Oct 2, 2026, Erez REIT Opportunities LP and Erez Asset Management LLC (reporting persons controlled by Bruce Schanzer) purchased approximately 10.4 million shares of Empire State Realty Trust Class A common stock in open-market transactions at prices ranging from $4.08–$4.46 per share. The aggregate acquisition value was roughly $43.5M. A joint filing agreement dated October 5, 2026 confirms coordinated reporting by both entities and Schanzer.
— Neutral
· significance 72 · Ownership Agent
SCHEDULE 13D/A
Phunware, Inc.
During August–October 2026, a filer purchased approximately 189,526 common shares of Phunware at prices ranging from $1.97 to $2.50, including 97,614 shares acquired via exercise of short put options at $2.50/share. Concurrently, the filer wrote and closed multiple short put and call option contracts, predominantly Oct 2026 and Jan 2027 expirations at $2.50 strike. Total aggregate acquisition cost approximately $376K–$396K (depending on option closing costs). This represents sustained insider accumulation signaling confidence in the stock despite its micro-cap size ($6.4M market value).
▲ Likely positive
· significance 71 · Ownership Agent
8-K
Immunome Inc.
On October 2, 2026, Bristol-Myers Squibb Company purchased 4,425,487 shares of Immunome common stock (approximately 3.9% of outstanding shares as of June 30, 2026: 113.4M shares) as partial consideration for Amendment No. 4 to their existing License Agreement dated November 29, 2017. Concurrently, BMS paid Immunome $20 million in cash and assigned certain patent rights (Transferred Patents, detailed in redacted Exhibit A) to Immunome. In exchange, Immunome granted BMS a perpetual, non-exclusive license under the Transferred Patents for molecules other than Immunome's Licensed Compounds and Licensed Products. The amendment significantly narrows Immunome's obligations: it eliminates milestone payments, royalty payments, development/commercialization diligence, and sales reporting requirements, and terminates BMS's patent rights license effective immediately.
— Neutral
· significance 68 · 8-K Agent
8-K
Evolution Metals & Technologies Corp.
Evolution Metals Technologies announced a December 17, 2026 ribbon-cutting ceremony for its Pohang, South Korea rare earth magnet facility, which it claims is the largest high-performance rare earth magnet facility in production outside China. The company plans a phased expansion targeting >10,000 metric tons of annual capacity, positioned ahead of January 1, 2027 DFARS restrictions on Chinese-origin magnets in U.S. defense systems and following an August 2026 White House 100% tariff proclamation on certain unmanned aircraft. No specific revenue figures, customer contracts, production volumes, or financing amounts are disclosed.
▲ Likely positive
· significance 68 · 8-K Agent
8-K
Korro Bio, Inc.
Korro Bio initiated its ANCHOR Phase 1/2 clinical trial for KRRO-121 on October 5, 2026, dosing the first cohort of healthy volunteers with a single 2mg/kg dose in Australia. The trial enrolls up to 50 healthy volunteers (30 SAD, 20 MAD, placebo-controlled) followed by Part 2 with up to 15 UCD patients; UCD patient dosing expected H1 2027 with interim readout H2 2027. No dollar amounts, financing, or material partnerships disclosed.
▲ Likely positive
· significance 68 · 8-K Agent
8-K
STANDARD BIOTOOLS INC.
Standard BioTools Inc. announced a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days, subject to customary closing conditions. The filing does not disclose the purchase price, financial terms, or the revenue/profitability contribution of the Microfluidics business being divested.
— Neutral
· significance 68 · 8-K Agent
8-K
NN INC
NN Inc. completed a registered direct offering on October 1, 2026, issuing approximately $51.13M in Common Stock and pre-funded warrants at $3.30/share and $3.29/warrant respectively. Purchasers received shares and pre-funded warrants (exercisable at $0.01) with a 4.99%–9.99% beneficial ownership limit, subject to an Exchange Cap of 19.99%. The offering included registration rights for resale, liquidated damages provisions for registration delays, and extensive anti-dilution and adjustment mechanisms in the warrant terms.
▲ Likely positive
· significance 68 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.